On April 25, 2025, Cyclacel Pharmaceuticals, Inc. amended its charter to increase its authorized common stock from 250 million to 600 million shares, with no changes to currently issued shares. They also removed limitations on Series E Convertible Preferred Stock allowing broader conversion and voting rights.